Abstract
Identification of surrogate markers for a marketed drug is important in monitoring the efficacy or safety after a patient uses the drug. In this article, we clarify the statistical definitions of the surrogate endpoint and surrogate marker and introduce the concept of the validity and efficiency of a surrogate marker. We also review some existing methods and suggest the proportion of information gain is appropriate to be used to evaluate the validity of a surrogate marker.
Users
Please
log in to take part in the discussion (add own reviews or comments).